Drugs /

nimotuzumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Trade Name(s):
Theraloc
NCI Definition [1]:
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.

Clinical Trials

View Clinical Trials for nimotuzumab

Nimotuzumab has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating nimotuzumab, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).

EBV Positive and EGFR Amplification are the most frequent biomarker inclusion criteria for nimotuzumab clinical trials.

Nasopharyngeal carcinoma, squamous cell lung carcinoma, and lung adenocarcinoma are the most common diseases being investigated in nimotuzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nimotuzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nimotuzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
h-r3, hr3, thera-cim-hr3, theracim hr3, Theraloc
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C2733

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.